Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
News articleYahoo Finance· April 17, 2026
New data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test
View original at finance.yahoo.comNew data at AACR 2026 demonstrate advancements in Cancerguard® Multi-Cancer Early Detection Test Data show how a multi-biomarker class approach improves early-stage cancer detection AACR will also recognize landmark DETECT-A study publication reporting long-term outcomes supporting the clinical impact of MCED ABBOTT PA…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Cancerguard is currently the only commercially available MCED test designed with a multi-biomarker class approach, combining methylation and protein signals to improve detection
60% confidenceDETECT-A study identified nine cancer types, including several without routine screening, and showed that after median follow-up of approximately four years, all patients treated for stage I or II cancers remained alive and cancer-free
60% confidenceBy combining biomarkers, Abbott can detect cancer earlier, when it matters most
60% confidenceCancerguard was designed as the first-of-its-kind multi-biomarker test because no one signal tells the whole story
60% confidence